NCT00316524View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects

PHASE2CompletedINTERVENTIONAL

Enrollment

745

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

August 31, 2007

Conditions

Smallpox

Interventions

BIOLOGICAL

MVA-BN® (IMVAMUNE)

1x 10E8\_TCID50

BIOLOGICAL

Placebo

Tris-Buffer

Trial Locations (1)

80636

Harrison Clinical Research GmbH, Munich

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Bavarian Nordic

INDUSTRY